264 related articles for article (PubMed ID: 2536060)
21. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of herpes simplex virus infection to target cells on recognition of minor histocompatibility antigens by cytotoxic T lymphocytes.
Kuzushima K; Isobe K; Morishima T; Takatsuki A; Nakashima I
J Immunol; 1990 Jun; 144(12):4536-40. PubMed ID: 2161874
[TBL] [Abstract][Full Text] [Related]
23. The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.
Carter VC; Schaffer PA; Tevethia SS
J Immunol; 1981 May; 126(5):1655-60. PubMed ID: 6971309
[TBL] [Abstract][Full Text] [Related]
24. Effects of herpes simplex virus on induced cell-mediated cytotoxicity in neonates and adults.
Chin TW; Plaeger-Marshall S; Ank BJ; Pressman SR; Stiehm ER
Nat Immun Cell Growth Regul; 1991; 10(5):237-46. PubMed ID: 1661847
[TBL] [Abstract][Full Text] [Related]
25. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
26. Differential in vitro activation of CD4+CD8- and CD8+CD4- herpes simplex virus-specific human cytotoxic T cells.
Yasukawa M; Inatsuki A; Kobayashi Y
J Immunol; 1989 Sep; 143(6):2051-7. PubMed ID: 2476493
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cells lyse autologous herpes simplex virus infected targets using cytolytic mechanisms distributed clonotypically.
Pietra G; Semino C; Cagnoni F; Boni L; Cangemi G; Frumento G; Melioli G
J Med Virol; 2000 Nov; 62(3):354-63. PubMed ID: 11055246
[TBL] [Abstract][Full Text] [Related]
28. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.
Titus JA; Perez P; Kaubisch A; Garrido MA; Segal DM
J Immunol; 1987 Nov; 139(9):3153-8. PubMed ID: 2959724
[TBL] [Abstract][Full Text] [Related]
29. Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji.
Fitzgerald-Bocarsly P; Feldman M; Curl S; Schnell J; Denny T
J Immunol; 1989 Aug; 143(4):1318-26. PubMed ID: 2526183
[TBL] [Abstract][Full Text] [Related]
30. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. III. Analysis of viral glycoproteins recognized by CTL clones by using recombinant herpes simplex viruses.
Yasukawa M; Zarling JM
J Immunol; 1985 Apr; 134(4):2679-82. PubMed ID: 2579149
[TBL] [Abstract][Full Text] [Related]
31. Role of interferon in human natural killer activity against target cells infected with HSV-1.
Bishop GA; Glorioso JC; Schwartz SA
J Immunol; 1983 Oct; 131(4):1849-53. PubMed ID: 6194217
[TBL] [Abstract][Full Text] [Related]
32. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2.
Rouse BT; Miller LS; Turtinen L; Moore RN
J Immunol; 1985 Feb; 134(2):926-30. PubMed ID: 2981270
[TBL] [Abstract][Full Text] [Related]
34. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
Perl A; Looney RJ; Ryan DH; Abraham GN
J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
[TBL] [Abstract][Full Text] [Related]
35. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
36. Natural killer cellular cytotoxicity against herpes simplex virus-infected cells in Igh-1-disparate mice.
Tamesis RR; Foster CS
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2224-9. PubMed ID: 1700771
[TBL] [Abstract][Full Text] [Related]
37. HLA-unrestricted killing of HSV-1-infected mononuclear cells. Involvement of either gamma/delta+ or alpha/beta+ human cytotoxic T lymphocytes.
Maccario R; Revello MG; Comoli P; Montagna D; Locatelli F; Gerna G
J Immunol; 1993 Feb; 150(4):1437-45. PubMed ID: 8381835
[TBL] [Abstract][Full Text] [Related]
38. Lysis of herpes simplex virus (HSV) infected targets. IV. HSV-induced change in the effector population.
Hendricks RL; Sugar J
Invest Ophthalmol Vis Sci; 1985 Feb; 26(2):208-13. PubMed ID: 3972502
[TBL] [Abstract][Full Text] [Related]
39. In vitro induction of human cell-mediated cytotoxicity directed against herpes simplex virus-infected cells: characterization of the effector lymphocyte.
Rola-Pleszczynski M
J Immunol; 1980 Oct; 125(4):1475-80. PubMed ID: 6967905
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of human NK cells: comparison of effectors that lyse HSV-1-infected fibroblasts and K562 erythroleukemia targets.
Fitzgerald PA; Evans R; Kirkpatrick D; Lopez C
J Immunol; 1983 Apr; 130(4):1663-7. PubMed ID: 6601135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
